Table 2.
Differentially expressed genes in three overrepresented biological processes associated with celecoxib pre-treatment
| Symbol | Gene Name | Fold Change |
|---|---|---|
| Cellular Lipid Metabolism: p<0.000002* | ||
| ACAA2 | acetyl-Coenzyme A acyltransferase 2 | −1.86 |
| ACADSB | acyl- Coenzyme A dehydrogenase, short/branched chain | −1.63 |
| AGPAT2 | 1-acylglycerol-3-phosphate O-acyltransferase 2 | −1.65 |
| AKR1C1/AKR1C2 | aldo-keto reductase family 1, member C | 1.72 |
| C14ORF1 | chromosome 14 open reading frame 1 | −1.58 |
| CDS1 | CDP-diacylglycerol synthase 1 | −2.89 |
| CYP2J2 | cytochrome P450, family 2, subfamily J, polypeptide 2 | −2.15 |
| DGAT1 | diacylglycerol O-acyltransferase homolog 1 (mouse) | −2.04 |
| DHCR24 | 24-dehydrocholesterol reductase | −1.55 |
| ECH1 | enoyl Coenzyme A hydratase 1, peroxisomal | −1.51 |
| FABP1 | fatty acid binding protein 1, liver | −2.82 |
| FDFT1 | farnesyl-diphosphate farnesyltransferase 1 | −1.58 |
| HADHSC | L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain | −2.33 |
| HMGCR | 3-hydroxy-3-methylglutaryl-Coenzyme A reductase | −1.81 |
| HSD17B2 | hydroxysteroid (17-beta) dehydrogenase 2 | −2.11 |
| HSD17B4 | hydroxysteroid (17-beta) dehydrogenase 4 | −1.66 |
| PCCA | propionyl Coenzyme A carboxylase, alpha polypeptide | −2.60 |
| PCCB | propionyl Coenzyme A carboxylase, beta polypeptide | −2.25 |
| PIGF | phosphatidylinositol glycan anchor biosynthesis, class F | −1.60 |
| RARRES2 | retinoic acid receptor responder (tazarotene induced) 2 | 1.75 |
| SLC27A2 | solute carrier family 27 (fatty acid transporter), member 2 | −2.54 |
| UGT1A1 - A10 | UDP glucuronosyltransferase 1 family | −2.84 |
| UGT8 | UDP glycosyltransferase 8 | −2.54 |
| Glutathione Metabolism: p<0.001* | ||
| GGT1 | gamma-glutamyltransferase 1 | −1.54 |
| GGT2 | gamma-glutamyltransferase 2 | −1.80 |
| GGTL4 | gamma-glutamyltransferase-like 4 | −2.12 |
| GSR | glutathione reductase | −1.67 |
| Cell Adhesion: p<0.02* | ||
| CCL2 | chemokine (C-C motif) ligand 2 | 2.62 |
| CIB1 | calcium and integrin binding 1 (calmyrin) | −1.64 |
| CLDN7 | claudin 7 | −1.71 |
| COL16A1 | collagen, type XVI, alpha 1 | 2.34 |
| CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | −1.68 |
| FCGBP | Fc fragment of IgG binding protein | −7.09 |
| GMDS | GDP-mannose 4,6-dehydratase | −2.07 |
| ITGA6 | integrin, alpha 6 | −1.58 |
| LAMA4 | laminin, alpha 4 | 1.81 |
| LGALS4 | lectin, galactoside-binding, soluble, 4 (galectin 4) | −2.57 |
| LOXL2 | lysyl oxidase-like 2 | 1.52 |
| MAEA | macrophage erythroblast attacher | −1.51 |
| MUC5AC | mucin 5AC, oligomeric mucus/gel-forming | −2.84 |
| PECAM1 | platelet/endothelial cell adhesion molecule (CD31 antigen) | 2.21 |
| TNC | tenascin C (hexabrachion) | 1.82 |
| TNFAIP6 | tumor necrosis factor, alpha-induced protein 6 | 1.93 |
| TSPAN1 | tetraspanin 1 | −2.61 |
| VCAM1 | vascular cell adhesion molecule 1 | 1.69 |
| VWF | von Willebrand factor | 1.80 |
NOTE: Fold change represents the difference in expression in celecoxib pre-treated patients versus patients receiving no drug pretreatment.
*
P-value represents the likelihood that the number of differentially expressed genes belonging to the biological process occurred by chance as determined by the Fischer’s exact test.